Evotec AG (NASDAQ:EVO) Receives Consensus Recommendation of “Hold” from Analysts

Evotec AG (NASDAQ:EVO) has received a consensus rating of “Hold” from the five analysts that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $3.00.

A number of research analysts recently weighed in on the company. Wall Street Zen downgraded Evotec from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. HC Wainwright decreased their target price on Evotec from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Wednesday. Weiss Ratings upgraded Evotec from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, April 24th. Berenberg Bank lowered shares of Evotec from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, TD Cowen cut shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price objective for the company. in a research note on Wednesday.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Apollon Wealth Management LLC acquired a new position in Evotec during the 1st quarter worth $28,000. Marshall Wace LLP acquired a new stake in shares of Evotec in the fourth quarter valued at about $40,000. SmartHarvest Portfolios LLC acquired a new stake in shares of Evotec in the first quarter valued at about $44,000. BNP Paribas Financial Markets increased its stake in shares of Evotec by 62.2% in the second quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock worth $50,000 after purchasing an additional 4,600 shares during the period. Finally, Bank of America Corp DE increased its stake in shares of Evotec by 262.5% in the fourth quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock worth $53,000 after purchasing an additional 9,289 shares during the period. 5.81% of the stock is currently owned by institutional investors and hedge funds.

Evotec Trading Down 0.5%

Shares of NASDAQ:EVO opened at $1.96 on Tuesday. Evotec has a fifty-two week low of $1.95 and a fifty-two week high of $4.42. The business has a 50-day moving average of $2.75 and a two-hundred day moving average of $3.01. The company has a quick ratio of 1.60, a current ratio of 1.68 and a debt-to-equity ratio of 0.43.

Key Evotec News

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Evotec AG and kept its $4.00 price target, signaling some confidence in longer-term upside.
• Neutral Sentiment: Analysts still expect Evotec to remain loss-making in the near term, with forecast EPS revisions showing only a gradual path toward profitability. Evotec AG stock page
• Negative Sentiment: HC Wainwright cut its Q3 2026 EPS estimate to ($0.04) from ($0.01), implying weaker-than-expected near-term earnings momentum.
• Negative Sentiment: The firm also lowered its Q4 2026 EPS forecast to ($0.02), reduced FY2026 EPS to ($0.31), and trimmed FY2027 EPS to $0.07, reinforcing concerns about slower earnings recovery.
• Negative Sentiment: Separately, Berenberg Bank downgraded Evotec from Buy to Hold, which likely added to the stock’s weakness by signaling less conviction in the near-term setup.

About Evotec

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.